secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001193125-22-217376
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q2 revenue $40.2M (+32% YoY); net loss of $0.7M vs prior-year net income $2.7M
--------------------------------------------------------------------------------

- Revenue $40.2M, up 32% YoY; gross profit $24.6M (61% margin) vs $19.7M (65% margin) prior year.
- Operating loss $0.9M vs operating income $3.8M in Q2 2021; net loss $0.7M vs prior net income $2.7M.
- Adjusted EBITDA $4.8M flat YoY; installed base 1,356 instruments (130 placed in quarter).
- Full-year 2022 revenue guidance reaffirmed: closer to high end of $160M-$168M range.
- Received CE mark for cFluor reagents and TBNK kit for European clinical market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522217376/0001193125-22-217376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522217376/d363001d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-217376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer